US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Organon & Co.

< Previous 1 2 3 Next >
News headline image
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 3 Next >